Activated platelet surface phospholipids (PF3) (PF3)

Activated platelet surface phospholipids, primarily phosphatidylserine (PS), are essential components of the hemostatic system that provide a catalytic surface for coagulation factor assembly [1]. In resting platelets, PS is maintained on the inner membrane leaflet by flippases, but upon activation by agonists like thrombin or collagen, it is rapidly translocated to the outer surface via the action of calcium-dependent scramblases such as TMEM16F [2]. This translocation creates a negatively charged platform that binds clotting factors IXa, VIIIa, Xa, and Va, facilitating the 'thrombin burst' necessary for stable fibrin clot formation [3]. Dysregulation of this process is linked to thrombotic disorders and Scott syndrome, a rare bleeding diathesis characterized by impaired phospholipid scrambling [4]. Therapeutic strategies targeting these phospholipids include imaging agents for detecting thrombi and proteins like Annexin V that block the procoagulant surface to prevent clot formation [5]. Additionally, PS-targeting antibodies are being explored in oncology and cardiovascular medicine to modulate immune responses and coagulation [6].

Other names

Platelet factor 3Procoagulant phospholipidsExposed phosphatidylserineAnionic phospholipidsProthrombotic phospholipids

The primary mechanism involves the high-affinity binding of therapeutic agents to exposed anionic phospholipids, specifically phosphatidylserine, on the outer leaflet of activated platelets. This binding sterically blocks the interaction sites for vitamin K-dependent coagulation factors (Factors II, VII, IX, and X) and their cofactors (Factors V and VIII), effectively preventing the assembly of the tenase and prothrombinase complexes and halting the amplification of the coagulation cascade [1, 3, 5].